Skip to main content

Table 5 Impact of marker status on clinical and pathological tumor features in TACE treated HCC

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

 

EpCAM

 

CD133

 
 

Low (n = 6)

High (n = 10)

P

Low (n = 4)

High (n = 12)

P

Age (year)

58(53–65)

56(48–68)

0.236

52(48–57)

58(49–68)

0.070

Gender (F/M)

1/5

1/9

0.696

0/4

2/12

0.383

AFP (ng/ml)

1333(4–7254)

256(3–2000)

0.289

297(8–43)

870(3–7254)

0.177

Interval between

189(82–345)

224(73–337)

0.479

260(188–327)

194(73–377)

0.217

TACE and Tx (days)

      

More than one TACE

1/6

3/10

0.639

2/4

2/12

0.329

Tumor Size (mm)

45(25–76)

34(20–55)

0.181

36(32–40)

39(20–76)

0.744

Tumor differentiation

  

0.024

  

0.834

Well

0

1

 

0

1

 

Moderately

6

3

 

3

8

 

Poor

0

6

 

1

3

 

TNM Stages

  

0.302

  

0.248

I

4

4

 

1

7

 

II

2

6

 

3

5